+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AAV Gene Therapy Drugs Market - Global Forecast 2025-2030- Product Image
AAV Gene Therapy Drugs Market - Global Forecast 2025-2030- Product Image
Sale

AAV Gene Therapy Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6145971
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Adeno-associated virus (AAV) gene therapy is transforming the treatment paradigm for genetic disorders, offering targeted solutions enabled by advanced vector engineering and evolving commercialization strategies. As clinical translation accelerates, industry leaders must navigate new manufacturing, tariff, and regulatory challenges to capitalize on growth opportunities.

Market Snapshot: AAV Gene Therapy Market

The AAV gene therapy market is experiencing robust momentum, driven by ongoing technological advances and a surge in clinical applications across hematology, neurology, metabolic, musculoskeletal, and ophthalmic indications. A growing number of trials and emerging commercial models highlight keen interest among biopharmaceutical stakeholders, healthcare providers, and payors. The market continues to expand globally, favored by increased funding activity and advancements in drug delivery and manufacturing innovation.

Scope & Segmentation

This report delivers detailed analysis and revenue forecasts across key segmentation and regional dynamics within the global AAV gene therapy sector.

  • Indication: The scope covers therapies targeting hematology (Beta Thalassemia, Hemophilia A, Hemophilia B), metabolic (Fabry Disease, Gaucher Disease), musculoskeletal (Becker Muscular Dystrophy, Duchenne Muscular Dystrophy), neurology (Alzheimer’s Disease, Parkinson’s Disease, Spinal Muscular Atrophy), and ophthalmology (Age Related Macular Degeneration, Leber’s Congenital Amaurosis, Retinal Dystrophy).
  • Vector Type: Analysis includes AAV2, AAV5, AAV8, and AAV9, with each delivering unique biodistribution and tissue-targeting profiles.
  • End-User: Reflects adoption trends among contract manufacturing organizations, hospitals, research institutes, and specialty clinics as principal environments for production and clinical implementation.
  • Administration Route: Coverage of intramuscular, intrathecal, intravenous, and subretinal delivery routes, which influence patient suitability and procedural requirements.
  • Therapy Stage: Insights span development maturity from preclinical research through Phase I–III trials to approved therapies.
  • Modality: Both monotherapy and combination therapy approaches are assessed for their impact on clinical design and commercial positioning.
  • Distribution Channel: Evaluates direct to patient, hospital pharmacy, and specialty pharmacy networks, revealing implications for access and logistics.
  • Region: Geographic coverage includes the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, UAE, Saudi Arabia, South Africa, and more), and Asia-Pacific (with detailed markets in China, India, Japan, Australia, South Korea, and Southeast Asia).
  • Leading Companies: The report analyzes developments in organizations such as Novartis AG, uniQure N.V., and Spark Therapeutics, Inc.

AAV Gene Therapy: Key Takeaways for Decision-Makers

  • Evolving patient stratification methods—now integrating genomic and biomarker data—enable more personalized AAV therapy selection, improving outcome predictability and patient targeting.
  • Innovative vector engineering (novel capsid variants and synthetic promoters) enhances tissue specificity and reduces immune response rates, paving the way for broader personalized gene delivery applications.
  • Manufacturing progress, including digital process analytics and modular technologies, boosts scale and consistency while reducing variability and production timelines.
  • Emerging commercial models, such as outcome-based or subscription-style pricing agreements, facilitate alignment between biopharma and payors, supporting market access for one-time curative therapies.
  • Regional market dynamics are shaped by regulatory harmonization, public–private research alliances, and localized manufacturing capacity, underscoring the need for tailored go-to-market strategies.

Tariff Impact: Managing Supply Chain and Cost Pressures

Imminent United States tariff adjustments will affect sourcing and increase upstream costs for bioprocessing reagents and specialized inputs. Companies are responding by diversifying supplier networks, leveraging domestic and nearshore partners, and intensifying collaborations with CDMOs to localize manufacturing and share risk. These shifts reinforce the value of robust supply chain management as the market responds to evolving trade policies.

Methodology & Data Sources

The analysis leverages primary interviews with stakeholders across biopharma, regulatory, and clinical domains, supplemented by secondary research spanning scientific literature and proprietary databases. Quantitative triangulation ensures high-fidelity trend validation and theme synthesis across all segments and regions.

Why This Report Matters

  • Enables executives to benchmark market position and refine AAV gene therapy portfolio and manufacturing strategies.
  • Delivers actionable intelligence on regulatory adaptation, tariff impact mitigation, and commercialization pathways to accelerate patient access and revenue realization.

AAV Gene Therapy Market: Conclusion

AAV gene therapy stands out as a high-growth arena, shaped by innovation in vector design, manufacturing, and value-based models. Grounded in rigorous research, this report equips senior decision-makers with clarity to drive sustainable leadership within the evolving landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in engineered AAV capsids to enhance tissue specificity and reduce immunogenicity
5.2. Regulatory progress and conditional approvals for novel AAV gene therapies targeting rare ophthalmic disorders
5.3. Large-scale biomanufacturing innovations to address production bottlenecks in clinical-grade AAV vector supply
5.4. Leveraging CRISPR-mediated genome editing delivery via AAV vectors for in vivo therapeutic correction
5.5. Strategic alliances between biopharmaceutical companies and CDMOs to strengthen AAV manufacturing capacity
5.6. Clinical evaluation of novel immunomodulatory regimens to overcome preexisting anti-AAV humoral responses
5.7. Implementation of AI-driven bioinformatics platforms to optimize AAV vector design and predict efficacy
5.8. Pipeline expansion into central nervous system indications using intrathecal AAV administration techniques
5.9. Adoption of quality-by-design principles and advanced analytics for robust AAV production process control
5.10. Emerging competition from nonviral delivery systems driving innovation in AAV gene therapy modalities
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. AAV Gene Therapy Drugs Market, by Indication
8.1. Introduction
8.2. Hematology
8.2.1. Beta Thalassemia
8.2.2. Hemophilia A
8.2.3. Hemophilia B
8.3. Metabolic
8.3.1. Fabry Disease
8.3.2. Gaucher Disease
8.4. Musculoskeletal
8.4.1. Becker Muscular Dystrophy
8.4.2. Duchenne Muscular Dystrophy
8.5. Neurology
8.5.1. Alzheimer’s Disease
8.5.2. Parkinson’s Disease
8.5.3. Spinal Muscular Atrophy
8.6. Ophthalmology
8.6.1. Age Related Macular Degeneration
8.6.2. Leber’s Congenital Amaurosis
8.6.3. Retinal Dystrophy
9. AAV Gene Therapy Drugs Market, by Vector Type
9.1. Introduction
9.2. AAV2
9.3. AAV5
9.4. AAV8
9.5. AAV9
10. AAV Gene Therapy Drugs Market, by End-User
10.1. Introduction
10.2. Contract Manufacturing Organizations
10.3. Hospitals
10.4. Research Institutes
10.5. Specialty Clinics
11. AAV Gene Therapy Drugs Market, by Administration Route
11.1. Introduction
11.2. Intramuscular
11.3. Intrathecal
11.4. Intravenous
11.5. Subretinal
12. AAV Gene Therapy Drugs Market, by Therapy Stage
12.1. Introduction
12.2. Approved
12.3. Phase I
12.4. Phase II
12.5. Phase III
12.6. Preclinical
13. AAV Gene Therapy Drugs Market, by Modality
13.1. Introduction
13.2. Combination Therapy
13.3. Monotherapy
14. AAV Gene Therapy Drugs Market, by Distribution Channel
14.1. Introduction
14.2. Direct To Patient
14.3. Hospital Pharmacy
14.4. Specialty Pharmacy
15. Americas AAV Gene Therapy Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa AAV Gene Therapy Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific AAV Gene Therapy Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. uniQure N.V.
18.3.3. Spark Therapeutics, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. AAV GENE THERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AAV GENE THERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. AAV GENE THERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. AAV GENE THERAPY DRUGS MARKET: RESEARCHAI
FIGURE 30. AAV GENE THERAPY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. AAV GENE THERAPY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. AAV GENE THERAPY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AAV GENE THERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY FABRY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY FABRY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY LEBER’S CONGENITAL AMAUROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY LEBER’S CONGENITAL AMAUROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY RETINAL DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY RETINAL DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV2, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV5, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV5, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV8, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY AAV9, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SUBRETINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SUBRETINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL AAV GENE THERAPY DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES AAV GENE THERAPY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 165. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 168. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 169. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 170. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 171. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 172. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 173. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 174. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 175. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 176. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 177. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 178. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 179. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 182. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 183. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 184. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 185. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 186. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 187. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. CANADA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 192. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 193. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 194. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 195. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 197. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 200. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 201. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 204. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 205. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 206. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 207. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 210. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 211. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. MEXICO AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY THERAPY STAGE, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM AAV GENE THERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 314. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 315. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2018-2024 (USD MILLION)
TABLE 316. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY METABOLIC, 2025-2030 (USD MILLION)
TABLE 317. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2018-2024 (USD MILLION)
TABLE 318. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY MUSCULOSKELETAL, 2025-2030 (USD MILLION)
TABLE 319. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 320. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 321. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
TABLE 322. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
TABLE 323. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 324. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 325. GERMANY AAV GENE THERAPY DRUGS MARKET SIZE, BY END-U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this AAV Gene Therapy Drugs market report include:
  • Novartis AG
  • uniQure N.V.
  • Spark Therapeutics, Inc.

Related Topics

Related Reports

Ophthalmic AAV Gene Therapy Market - Global Forecast 2025-2030 - Product Image

Ophthalmic AAV Gene Therapy Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
AAV Gene Therapy Injection Market - Global Forecast 2025-2030 - Product Image

AAV Gene Therapy Injection Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2025 - Product Image

Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 400 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region - Product Image

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region

  • Report
  • 768 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.